locally advanced, Non-small cell lung cancer (NSCLC), older patients, chemoradiotherapy, daily low-dose carboplatin, carboplatin plus nab-paclitaxel
Small cell lung cancer, transformation, rebiopsy, tumor surface protein, antibody drug conjugate